Oct 7, 2026 07:30AM
Oct 7, 2026 07:30AM
Sep 1, 2026 09:07AM
Aug 30, 2026 11:30AM
Aug 30, 2026 11:30AM
Aug 24, 2026 07:30AM
Aug 4, 2026 04:01PM Arrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results
Aug 4, 2026 04:00PM
Aug 4, 2026 04:00PM
Aug 4, 2026 04:00PM
Jul 27, 2026 06:47AM
Jul 22, 2026 07:30AM
Jul 22, 2026 07:30AM
Jun 22, 2026 12:36PM EU approves Arrowhead's plozasiran for rare triglyceride disorder
Jun 22, 2026 12:33PM
May 26, 2026 10:00AM
May 26, 2026 10:00AM
May 7, 2026 04:01PM
May 1, 2026 07:30AM
May 1, 2026 07:30AM
Apr 24, 2026 06:39AM ARWR receives positive EU opinion for REDEMPLO to treat rare genetic disorder
Apr 24, 2026 06:39AM
Mar 30, 2026 04:21AM
Mar 28, 2026 10:30AM
Mar 26, 2026 02:33PM
Feb 17, 2026 08:30AM
Feb 5, 2026 04:05PM
Jan 7, 2026 07:32AM Arrowhead receives China approval for rare disease drug REDEMPLO
Jan 7, 2026 07:30AM
Jan 5, 2026 07:30AM
Jan 5, 2026 07:30AM
Dec 22, 2025 07:06AM
Dec 21, 2025 04:00AM
Dec 19, 2025 09:06AM
Dec 2, 2025 07:30AM Arrowhead gets FDA breakthrough therapy status for plozasiran drug
Dec 2, 2025 07:30AM
Nov 25, 2025 04:00PM
Nov 19, 2025 09:14AM
Nov 19, 2025 09:06AM
Nov 19, 2025 08:51AM
Nov 18, 2025 11:52AM
Nov 18, 2025 11:52AM Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
Nov 18, 2025 11:17AM
Oct 24, 2025 08:29AM
Sep 11, 2025 07:30AM
Sep 11, 2025 07:30AM
Aug 7, 2025 04:01PM
Aug 1, 2025 06:30AM
Aug 1, 2025 06:30AM Arrowhead Subsidiary Visirna Sells Rights to Hypertriglyceridemia Candidate Plozasiran in Greater China to Sanofi
Jun 23, 2025 07:30AM

333,790 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All